ucsf banner
Helen Diller Family Compr Cancer Ctr
EMILY K. BERGSLAND, MD

Associate Professor, Medicine, UCSF

CONTACT

(415) 353-9888 (appts)
(415) 353-9959 (fax)

Box 1705, UCSF; San Francisco, CA 94143-1705

additional websites:

UCSF Physician Referral Directory

EDUCATION

University of Wisconsin, B.S., 1985, Biochemistry and Molecular Biology
University of Minnesota, M.D., 1989

PROFESSIONAL EXPERIENCE

1989-90

Intern, Dept. of Medicine, University of California San Francisco

1990-92

Resident, Dept. of Medicine, University of California San Francisco

1992-93

Chief Resident and Assistant Chief of the Medical Service, Dept. of Medicine, University of California San Francisco

1993-95

Fellow, Medical Oncology, University of California San Francisco

1994-1999

Research Fellow (P I: Douglas Hanahan, Ph.D.), Department of Biochemistry and Biophysics, University of California San Francisco
Transgenic mouse models of tumorigenesis

1996-1998

Clinical Instructor, Dept. of Medicine (Division of Hematology/Oncology), UCSF

1998-2004

Assistant Clinical Professor, Dept of Medicine (Division of Hematology/Oncology), UCSF

2003-2006

Associate Director, Hematology/Oncology Fellowship Program, UCSF

2004-present

Associate Professor, Dept. of Medicine, Division of Hematology/Oncology, UCSF

2006-present

Director of Education and Fellowship Program Director, Hematology/Oncology

HONORS & AWARDS

1984

Phi Beta Kappa

1985-89

Vine Scholarship, University of Minnesota

1989

May Sine Peterson Award, University of Minnesota

1989

Alpha Omega Alpha

1995-98

Molecular Medicine Fellowship, University of California San Francisco

SELECTED PUBLICATIONS

Bullard KM, Banda MJ, Arbeit JM, Bergsland EK, Young DM. Human Acellular Dermal Matrix as a Novel Model of Malignant Epithelial Cell Invasion. Invasion and Metastasis. 1997; 17: 42-52.

Hanahan D, Bergers G, & Bergsland E. Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. Journal of Clinical Investigation. 2000: 105: 1045-1047.

Kabbinavar F, Hurwitz H, Fehrenbacher L., Meropol L, Novotny W, Gaudreault J, Lieberman G, Bergsland E. A Randomized Phase II Trial comparing rhuMAb VEGF Plus 5-Fluorouracil/Leucovorin (FU/LV) to Chemotherapy Alone in Patients with Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2003; 21: 60-65.

Ko A, Bergsland E, & Lee G. TumorŠassociated hypoglycemia from metastatic colorectal adenocarcinoma: Case report and review of the literature. Digestive Diseases and Sciences 48; 192-196, 2003.

Daniel D, Meyer-Morse N, Bergsland E, Dehne K, Coussens L, Hanahan D. Immune Enhancement of Squamous Epithelial Carcinogenesis by CD4+ T cells. Journal of Experimental Medicine 197; 1017-1028, 2003.

Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with tyrosine kinase inhibitors. Journal of Clinical Investigation 111; 1287-95, 2003.

Mohr D, Moran P, Kohn C, Hart S, Armstrong K, Dias R, Bergsland E Folkman S. Couples therapy at end of life. Psycho-Oncology 12: 620-627, 2003.

Mehta K, Nakao K, Zuraek M, Ruan D, Bergsland E, Venook A, Fridlyand J, Moore D, Jain A, Warren R, Terdiman J, Waldman F. Fractional genomic alteration detected by array-based comparative genomic hybridization predicts survival after hepatic resection for metastatic colorectal cancer. Clinical Cancer Research, 2005;11: 1791-7.

Kabbinavar F. Hambleton J, Mass R, Hurwitz H, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. Journal of Clinical Oncology, 2005;23: 3706-12.

Ko, A., Hwang J, Venook A, Abbruzzese JL, Bergsland E, Tempero M. Using serum CA 19-9 response as a surrogate for clinical outcome in patients with advanced pancreatic cancer treated with fixed-dose rate gemcitabine. Br J Cancer, 2005; 93: 195-9.

Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA. Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas. J Clin Oncol. 2006 ;24(3):379-85.

Rajpal S, Warren R, Alexander M, Yeh B, Grenert J, Hintzen S, Ljung, BM, Bergsland E. Pancreatoblastoma in an adult. Journal of Gastrointestinal Surgery. 2006, Jun;10(6):829-36.

Kulke MH, Bergsland EK, Ryan DP, Enzinger PC, Lynch TJ, Zhu AX, Meyerhardt JA, Heymach JV, Fogler WE, Sidor C, Michelini A, Kinsella K, Venook AP, Fuchs CS. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol. 2006, Aug 1;24(22):3555-61.

12/8/06

This site will look much better in a browser that supports web standards, but it is accessible to any browser or Internet device. Please upgrade your browser.